After Hours Movers 8/7: ANADIGICS (ANAD) Sinks On Guidance; Crocs (CROX) Falls On Results

August 7, 2008 6:23 PM EDT

StreetInsider.com After Hours Movers:

Par Pharmaceutical Companies, Inc. (NYSE: PRX) 23% LOWER; reports a Q2 loss of $0.59, which may not compare to the analyst estimate of $0.12. Revenues for the quarter were $113 million, versus the consensus of $144 million.

ANADIGICS, Inc. (Nasdaq: ANAD) 22% LOWER; lowered third quarter 2008 financial guidance. Net sales for the third quarter 2008 are now estimated to be in the range of $62 million to $65 million. The consensus is $78.03 million. Net loss per share on a GAAP basis for the third quarter 2008 is expected to approximate $0.08 to $0.10. Pro forma per share results, excluding non-cash stock compensation expense, are expected in the range of income of $0.01 to a loss of $0.01. The consensus is $0.12 profit.

Magma Design Automation Inc. (Nasdaq: LAVA) 13% LOWER; sees Q1 total revenue of $44.5 million to $45.5 million, compared to its previous target revenue range of $50.0 million to $51.5 million, and the consensus of $50.5 million. Magma estimates Q1 non-GAAP earnings per share to be in the range of $(0.04) to $0.01, compared to its previous target range of $0.07 to $0.09 and the consensus of $0.08.

Jazz Pharmaceuticals (Nasdaq: JAZZ) 10% LOWER; reports a Q2 loss of $2.17, versus the analyst estimate of ($1.78). Revenues for the quarter were $15.5 million, versus the consensus of $20.19 million.

EnerNOC (Nasdaq: ENOC) 7% LOWER; reports a Q2 loss of $0.54, 3 cents better than the analyst estimate of ($0.57). Revenues for the quarter were $23.7 million, versus the consensus of $19.39 million.

Crocs, Inc. (Nasdaq: CROX) 7% LOWER; reports Q2 EPS of $0.06, ex-items, 1 cent better than the analyst estimate of $0.05. Revenues for the quarter were $222.8 million, versus the consensus of $219.73 million. Sees Q3 EPS of $0.01-$0.05, versus the consensus of $0.03.

Hertz Global Holdings Inc. (NYSE: HTZ) 6% LOWER; reports Q2 EPS of $0.30, 1 cents better than the analyst estimate of $0.29. Revenues for the quarter were $2.3 billion, versus the consensus of $2.24 billion. Sees 2008 EPS of $1.05-$1.15, versus the consensus of $1.29.

Emulex (NYSE: ELX) 4% LOWER; reports Q2 EPS of $0.22, 1 cent better than the analyst estimate of $0.21. Revenues for the quarter were $112.8 million, versus the consensus of $113.96 million. Emulex sees q1 eps 18-20 cents versus 22 cents consensus. Sees q1 revenuess $108-$111 million versus $116 million consensus.

Metabasis Therapeutics, Inc. (Nasdaq: MBRX) 4% HIGHER; entered into a two-year research collaboration agreement with Roche to apply Metabasis’ HepDirect liver-targeting technology to Roche’s proprietary lead nucleosides in order to develop new treatments for hepatitis C virus (HCV).

Deckers Outdoor (Nasdaq: DECK) 1% HIGHER; reports Q2 EPS of $0.39 ex-items or 28 cents headline, versus the analyst estimate of $0.24. Revenues for the quarter were $91.1 million, versus the consensus of $78.58 million. Sees FY08 revenue up 43% versus prior guidance of up 31%.

Gibraltar Industries, Inc. (Nasdaq: ROCK) INDICATED HIGHER; reports Q2 EPS of $0.67, versus the analyst estimate of $0.38. Revenues for the quarter were $379.2 million, versus the consensus of $364.26 million. Sees FY08 EPS of $1.50-$1.65, versus the consensus of $1.15.

Get This Report E-Mailed To You Daily and Much, Much More With StreetInsider.com Premium - FREE TRIAL

Related Categories

Special Reports

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?